Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Abstract 5512: Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven byKRAS^G12C amplification or NRAS^G13R mutation

Hitendra Singh Solanki, Denis Imbody, Bina Desai, Daria Miroshnychenko, Bhaswati Sarcar, Anurima Majumder, Yonghong Zhang, Uwe Rix, Andriy Marusyk, Mallika Singh, Ida Aronchik, Eric B. Haura

Cancer Res (2025) 85 (8_Supplement_1): 5512.

https://doi.org/10.1158/1538-7445.AM2025-5512

Published: 21 April 2025

View articletitled, Abstract 5512: Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven byKRASG12C amplification or NRASG13R mutation

Journal Articles

Abstract 1872: MSH6 modulates PARP inhibitor sensitivity in BRCA-proficient high-grade serous ovarian cancer

Ou Deng, Thales Nepomuceno, Bin Fang, Eric A. Welsh, Rachael H. Martin, Erin M. George, Alvaro N. Monteiro, Uwe Rix

Cancer Res (2025) 85 (8_Supplement_1): 1872.

https://doi.org/10.1158/1538-7445.AM2025-1872

Published: 21 April 2025

View articletitled, Abstract 1872: MSH6 modulates PARP inhibitor sensitivity in BRCA-proficient high-grade serous ovarian cancer

Journal Articles

Abstract A060 Investigating underlying efficacy and mechanism of action of the KIF11 inhibitor filanesib in Ewing and clear cell sarcomas

Hannah L. Walker-Mimms, Nicole Londono, Yi Liao, Neelkamal Chaudhary, Mingxiang Teng, Fumi Kinose, Xueli Li, Andrii Monastyrskyi, Uwe Rix, Derek Duckett

Cancer Res (2024) 84 (17_Supplement): A060.

https://doi.org/10.1158/1538-7445.PEDIATRIC24-A060

Published: 05 September 2024

View articletitled, Abstract A060 Investigating underlying efficacy and mechanism of action of the KIF11 inhibitor filanesib in Ewing and clear cell sarcomas

Journal Articles

Abstract CT057: Phase 1/2 trial of trametinib + ceritinib in patients with unresectable melanoma

Zeynep Eroglu, Vivien Yin, Joseph Markowitz, Andrew Brohl, Ahmad A. Tarhini, Wenyi Fan, Deanryan De Aquino, Ann Chen, Uwe Rix, Nikhil I. Khushalani, Keiran Smalley

Cancer Res (2024) 84 (7_Supplement): CT057.

https://doi.org/10.1158/1538-7445.AM2024-CT057

Published: 05 April 2024

View articletitled, Abstract CT057: Phase 1/2 trial of trametinib + ceritinib in patients with unresectable melanoma

Journal Articles

Abstract 647: FDA approved library screen revealed Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types

Hannah L. Walker-Mimms, Nicole Londono, Yi Liao, Neelkamal Chaudhary, Dessiree Pena Gomez, Yonghong Zhang, Mingxiang Teng, Uwe Rix, Derek R. Duckett

Cancer Res (2024) 84 (6_Supplement): 647.

https://doi.org/10.1158/1538-7445.AM2024-647

Published: 22 March 2024

View articletitled, Abstract 647: FDA approved library screen revealed Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types

Journal Articles

PTEN Lipid Phosphatase Activity Suppresses Melanoma Formation by Opposing an AKT/mTOR/FRA1 Signaling Axis

Xiaonan Xu, Ilah Bok, Neel Jasani, Kaizhen Wang, Manon Chadourne, Nicol Mecozzi, Ou Deng, Eric A. Welsh, Fumi Kinose, Uwe Rix, Florian A. Karreth

Cancer Res (2024) 84 (3): 388–404.

https://doi.org/10.1158/0008-5472.CAN-23-1730

Published: 01 February 2024

View articletitled, PTEN Lipid Phosphatase Activity Suppresses Melanoma Formation by Opposing an AKT/mTOR/FRA1 Signaling Axis

Includes: Supplementary data

Journal Articles

Abstract 552: Stromal facilitated multifactorial resistance to tumor cells against targeted therapies in ALK+ NSCLC

Bina Desai, Tatiana Miti, Daria Miroshnychenko, Viktoriya Marusyk, Chandler Gatenbee, Menkara Henry, Uwe Rix, Alexander Anderson, Eric Haura, David Basanta, Andriy Marusyk

Cancer Res (2023) 83 (7_Supplement): 552.

https://doi.org/10.1158/1538-7445.AM2023-552

Published: 04 April 2023

View articletitled, Abstract 552: Stromal facilitated multifactorial resistance to tumor cells against targeted therapies in ALK+ NSCLC

Journal Articles

Abstract 3839: Discovery of GSTZ1 as a novel target for drug refractory non-small cell lung cancer by using fragment-based chemical proteomics

Yi Liao, Sean Chin Chan, Eric A. Welsh, Bin Fang, Luxin Sun, Ernst Schönbrunn, John M. Koomen, Derek R. Duckett, Eric B. Haura, Andrii Monastyrskyi, Uwe Rix

Cancer Res (2023) 83 (7_Supplement): 3839.

https://doi.org/10.1158/1538-7445.AM2023-3839

Published: 04 April 2023

View articletitled, Abstract 3839: Discovery of GSTZ1 as a novel target for drug refractory non-small cell lung cancer by using fragment-based chemical proteomics

Journal Articles

Abstract 3193: Impact of stromal protection on in vivo response to ALK targeted therapies in NSCLC

Bina Desai, Viktoriya Marusyk, Daria Miroshnychenko, Chandler Gatenbee, Uwe Rix, Alexander Anderson, Eric Haura, Andriy Marusyk

Cancer Res (2022) 82 (12_Supplement): 3193.

https://doi.org/10.1158/1538-7445.AM2022-3193

Published: 15 June 2022

View articletitled, Abstract 3193: Impact of stromal protection on in vivo response to ALK targeted therapies in NSCLC

Journal Articles

Abstract B012: Impact of stromal protection on in-vivo response to ALK targeted therapies in NSCLC

Bina Desai, Viktoriya Marusyk, Daria Miroshnychenko, Chandler Gatenbee, Uwe Rix, Alexander Anderson, Eric Haura, Andriy Marusyk

Cancer Res (2022) 82 (10_Supplement): B012.

https://doi.org/10.1158/1538-7445.EVODYN22-B012

Published: 15 May 2022

View articletitled, Abstract B012: Impact of stromal protection on in-vivo response to ALK targeted therapies in NSCLC

Journal Articles

Abstract 3410: Adaptive resistance mechanisms to KRAS^G12C specific inhibitors

Hitendra Singh Solanki, Bin Fang, Eric A. Welsh, Aik C. Tan, Fumi Kinose, Uwe Rix, Eric B. Haura

Cancer Res (2020) 80 (16_Supplement): 3410.

https://doi.org/10.1158/1538-7445.AM2020-3410

Published: 15 August 2020

View articletitled, Abstract 3410: Adaptive resistance mechanisms to KRASG12C specific inhibitors

Journal Articles

Abstract 5511: Frontline therapy with anti-PD1 enhances the durability of combination targeted therapy in NRAS-mutant melanoma

Manali S. Phadke, Zhihua Chen, Eslam Mohamed, Michael Davies, Ann Chen, Uwe Rix, Paulo Rodriguez, Keiran Smalley

Cancer Res (2020) 80 (16_Supplement): 5511.

https://doi.org/10.1158/1538-7445.AM2020-5511

Published: 15 August 2020

View articletitled, Abstract 5511: Frontline therapy with anti-PD1 enhances the durability of combination targeted therapy in NRAS-mutant melanoma

Journal Articles

Abstract 5680: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors

Cancer Res (2020) 80 (16_Supplement): 5680.

https://doi.org/10.1158/1538-7445.AM2020-5680

Published: 15 August 2020

View articletitled, Abstract 5680: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors

Journal Articles

MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie, Hong Zheng, Ranjna Madan-Lala, Wenjie Dai, Nicholas T. Gimbrone, Zhihua Chen, Fumi Kinose, Sarah A. Blackstone, Keiran S.M. Smalley, W. Douglas Cress, Eric B. Haura, Uwe Rix, Amer A. Beg

Cancer Res (2019) 79 (22): 5812–5825.

https://doi.org/10.1158/0008-5472.CAN-19-0698

Published: 15 November 2019

View articletitled, MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Includes: Supplementary data

Journal Articles

Abstract 5089: A quantitative proteomic survey reveals mechanisms of the bi-directional signaling between lung fibroblasts and lung cancer cells

MARTIAL BOUTCHUENG DJIDJOU, Jae-Young KIM, Ki-Cheol Han, Gabriela Wright, Anurima Majumder, Bin Fang, John Koomen, Lily.L Remsing Rix, Uwe Rix, Eric Haura

Cancer Res (2018) 78 (13_Supplement): 5089.

https://doi.org/10.1158/1538-7445.AM2018-5089

Published: 01 July 2018

View articletitled, Abstract 5089: A quantitative proteomic survey reveals mechanisms of the bi-directional signaling between lung fibroblasts and lung cancer cells

Journal Articles

Abstract 2882: Elucidation of the mechanism of action of the multi-kinase inhibitor midostaurin in NSCLC

Claudia Ctortecka, Brent Kuenzi, Bin Fang, Natalia Sumi, Victoria Izumi, Fumi Kinose, Eric Haura, John Koomen, Uwe Rix

Cancer Res (2018) 78 (13_Supplement): 2882.

https://doi.org/10.1158/1538-7445.AM2018-2882

Published: 01 July 2018

View articletitled, Abstract 2882: Elucidation of the mechanism of action of the multi-kinase inhibitor midostaurin in NSCLC

Journal Articles

Abstract 3973: Dabrafenib suppresses the growth of BRAF-WT cancers through inhibition of novel targets Nek9 and Cdk16

Manali S. Phadke, Lily Rix, Inna Smalley, Annamarie Bryant, Harshani Lawrence, Braydon Schaible, Ann Chen, Uwe Rix, Keiran Smalley

Cancer Res (2018) 78 (13_Supplement): 3973.

https://doi.org/10.1158/1538-7445.AM2018-3973

Published: 01 July 2018

View articletitled, Abstract 3973: Dabrafenib suppresses the growth of BRAF-WT cancers through inhibition of novel targets Nek9 and Cdk16

Journal Articles

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases

Aria Vaishnavi, Laura Schubert, Uwe Rix, Lindsay A. Marek, Anh T. Le, Stephen B. Keysar, Magdalena J. Glogowska, Matthew A. Smith, Severine Kako, Natalia J. Sumi, Kurtis D. Davies, Kathryn E. Ware, Marileila Varella-Garcia, Eric B. Haura, Antonio Jimeno, Lynn E. Heasley, Dara L. Aisner, Robert C. Doebele

Cancer Res (2017) 77 (13): 3551–3563.

https://doi.org/10.1158/0008-5472.CAN-17-0109

Published: 02 July 2017

View articletitled, EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases

Includes: Supplementary data

Journal Articles

Abstract 221: Integrated functional proteomics of MET/VEGFR inhibitors reveals complex mechanism of action of foretinib in NSCLC

Natalia J. Sumi, Bin Fang, Lily L. Rix, Muhammad Ayaz, Fumi Kinose, Eric A. Welsh, Steven A. Eschrich, Harshani R. Lawrence, John M. Koomen, Eric B. Haura, Uwe Rix

Cancer Res (2017) 77 (13_Supplement): 221.

https://doi.org/10.1158/1538-7445.AM2017-221

Published: 01 July 2017

View articletitled, Abstract 221: Integrated functional proteomics of MET/VEGFR inhibitors reveals complex mechanism of action of foretinib in NSCLC

Journal Articles

Abstract 675: Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia

Brent M. Kuenzi, Lily L. Remsing Rix, Sateesh S. Kunigal, Fumi Kinose, Claire E. Knezevic, Gabriela Wright, Jodi L. Kroeger, Jeffrey E. Lancet, Eric Padron, Uwe Rix

Cancer Res (2015) 75 (15_Supplement): 675.

https://doi.org/10.1158/1538-7445.AM2015-675

Published: 01 August 2015

View articletitled, Abstract 675: Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 5512: Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven byKRAS^G12C amplification or NRAS^G13R mutation

Abstract 1872: MSH6 modulates PARP inhibitor sensitivity in BRCA-proficient high-grade serous ovarian cancer

Abstract A060 Investigating underlying efficacy and mechanism of action of the KIF11 inhibitor filanesib in Ewing and clear cell sarcomas

Abstract CT057: Phase 1/2 trial of trametinib + ceritinib in patients with unresectable melanoma

Abstract 647: FDA approved library screen revealed Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types

PTEN Lipid Phosphatase Activity Suppresses Melanoma Formation by Opposing an AKT/mTOR/FRA1 Signaling Axis

Abstract 552: Stromal facilitated multifactorial resistance to tumor cells against targeted therapies in ALK+ NSCLC

Abstract 3839: Discovery of GSTZ1 as a novel target for drug refractory non-small cell lung cancer by using fragment-based chemical proteomics

Abstract 3193: Impact of stromal protection on in vivo response to ALK targeted therapies in NSCLC

Abstract B012: Impact of stromal protection on in-vivo response to ALK targeted therapies in NSCLC

Abstract 3410: Adaptive resistance mechanisms to KRAS^G12C specific inhibitors

Abstract 5511: Frontline therapy with anti-PD1 enhances the durability of combination targeted therapy in NRAS-mutant melanoma

Abstract 5680: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors

MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Abstract 5089: A quantitative proteomic survey reveals mechanisms of the bi-directional signaling between lung fibroblasts and lung cancer cells

Abstract 2882: Elucidation of the mechanism of action of the multi-kinase inhibitor midostaurin in NSCLC

Abstract 3973: Dabrafenib suppresses the growth of BRAF-WT cancers through inhibition of novel targets Nek9 and Cdk16

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases

Abstract 221: Integrated functional proteomics of MET/VEGFR inhibitors reveals complex mechanism of action of foretinib in NSCLC

Abstract 675: Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only